Acadia Pharmaceuticals | ACAD - Operating Profit



Acadia Pharmaceuticals reported $32.37M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
ALKERMES USD 92.98M 79.19M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Corcept Therapeutics USD 26.67M 23.26M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
Eisai JPY 20.74B 21.77B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Prothena USD -52010000 12.89M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025